Stockscreener 앱 받기
4.12
1.20%
-0.05
시간 외 거래:
4.16
0.04
+0.97%
전일 마감가:
$4.17
열려 있는:
$4.24
하루 거래량:
4.77M
Relative Volume:
2.07
시가총액:
$362.04M
수익:
$30.91M
순이익/손실:
$-209.47M
주가수익비율:
-1.238
EPS:
-3.3279
순현금흐름:
$-147.13M
1주 성능:
+4.57%
1개월 성능:
-3.29%
6개월 성능:
-46.84%
1년 성능:
-20.62%
1일 변동 폭
$4.11
$4.425
1주일 범위
$3.85
$4.425
52주 변동 폭
$3.55
$11.24
Verastem Inc Stock (VSTM) Company Profile
명칭
Verastem Inc
전화
(781) 292-4200
주소
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
4.12 | 362.04M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 재개 | BTIG Research | Buy |
| 2026-02-04 | 개시 | H.C. Wainwright | Buy |
| 2025-10-16 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-04-10 | 개시 | Jefferies | Buy |
| 2025-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-31 | 재확인 | BTIG Research | Buy |
| 2024-09-30 | 개시 | Guggenheim | Buy |
| 2023-11-21 | 재개 | BTIG Research | Buy |
| 2023-09-27 | 개시 | B. Riley Securities | Buy |
| 2023-06-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-07 | 재개 | Alliance Global Partners | Buy |
| 2022-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2022-03-09 | 개시 | Truist | Buy |
| 2021-07-01 | 개시 | Alliance Global Partners | Buy |
| 2021-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2019-06-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 개시 | BTIG Research | Buy |
| 2018-05-02 | 개시 | Seaport Global Securities | Buy |
| 2018-03-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-13 | 개시 | Oppenheimer | Outperform |
| 2017-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2015-09-29 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-09-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2015-09-28 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-05-12 | 재확인 | UBS | Buy |
| 2015-04-08 | 개시 | H.C. Wainwright | Buy |
| 2015-01-23 | 재확인 | ROTH Capital | Buy |
| 2014-07-08 | 재개 | Oppenheimer | Perform |
| 2014-02-11 | 개시 | Mizuho | Buy |
모두보기
Verastem Inc 주식(VSTM)의 최신 뉴스
Verastem And The Biotech Side Of Penny Stocks - Kalkine Media
Verastem stock holds Outperform at Mizuho on pancreatic trial data - Investing.com
Verastem Inc (VSTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Verastem Inc (VSTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Verastem Inc (VSTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Verastem Inc (VSTM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Verastem (VSTM) Reveals Promising Results in Pancreatic Cancer S - GuruFocus
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
Verastem: 'Buy' Positive RAMP-205 Data And Extensive VS-7375 Registration Program (VSTM) - Seeking Alpha
Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer - Benzinga
Verastem Oncology reports positive RAMP 205 data in front-line pancreatic cancer - grafa.com
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Verastem (Nasdaq: VSTM) reports RAMP 205 pancreatic data and starts KRAS G12D trial - Stock Titan
Pancreatic cancer trial shows 86% six-month survival on Verastem drug combo - Stock Titan
Verastem Inc (VSTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Verastem (VSTM) Begins Patient Dosing in Crucial Cancer Trial - GuruFocus
Verastem Inc (VSTM) Institutional Confidence - TradingKey
Verastem Inc (VSTM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Verastem Inc (VSTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375 - TipRanks
Verastem, Inc. initiates first dosing in Phase 2 trial for KRAS G12D pancreatic cancer therapy - Traders Union
Verastem Oncology announced that its oral inhibitor VS-7375, targeting Kras G12d-mutated metastatic pancreatic cancer, has completed dosing for the first patient in the Target-D 201 phase II registration-directed study. - Bitget
Verastem doses first patient in pancreatic cancer trial By Investing.com - Investing.com Nigeria
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer - Business Wire
First patient receives KRAS G12D pill for metastatic pancreatic cancer - Stock Titan
Verastem, Inc. plans conference to unveil progress on KRAS G12D trial - Traders Union
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program - Business Wire
Verastem, Inc. Stock Plummets to New 52-Week Low of $3.56 - MarketsMojo
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM) - The Globe and Mail
VSTM Technical Analysis & Stock Price Forecast - Intellectia AI
Verastem’s VS-7375 receives FDA fast track status for lung cancer - Investing.com UK
Verastem announces FDA Fast Track designation for VS-7375 - TipRanks
Verastem Inc. (VSTM) Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Ongoing Clinical ProgressEPS Surprise History - newsline.com
Verastem, Inc. receives U.S. FDA fast track for KRAS G12D inhibitor in NSCLC treatment - Traders Union
Verastem (VSTM) Surges 11% Following FDA Fast Track Designation - GuruFocus
Verastem’s VS-7375 receives FDA fast track status for lung cancer By Investing.com - Investing.com South Africa
Verastem (VSTM) Receives Fast Track Designation for Cancer Treat - GuruFocus
Verastem stock rises on FDA fast track for lung cancer drug - Investing.com Canada
Verastem Initiates Phase 2 Target-D 202 Trial For Advanced NSCLC - TradingView
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung - Business Wire
Verastem Inc stock (US92335V1008): Nasdaq-listed oncology player steadies around late-May levels - AD HOC NEWS
VSTM Stock Price, Quote & Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Verastem (VSTM) Declines 2.5% as Biotech Sector Headwinds PersistPullback Trade - thelegaladvocate.com
Verastem (NASDAQ: VSTM) director receives 108,000 restricted stock units - Stock Titan
New Verastem (NASDAQ: VSTM) director files initial Form 3 ownership - Stock Titan
[144] Verastem, Inc. SEC Filing - Stock Titan
Biopharma Verastem Oncology joins Jefferies healthcare fireside chat June 3 - Stock Titan
Verastem Oncology to Present at Jefferies Healthcare Conference - marketscreener.com
Verastem: Robert Gagnon Stepped Down From Board Following End of Term on May 21 >VSTM - Moomoo
Director at Verastem (VSTM) receives 36,000 RSUs as equity award - Stock Titan
Verastem Inc (VSTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):